Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Cara Therapeutics ( (CARA) ).
On December 17, 2024, Cara Therapeutics announced a merger with Tvardi Therapeutics, which will see Tvardi become a wholly-owned subsidiary. The merger, expected to close in mid-April 2025, will result in the combined company being renamed Tvardi Therapeutics, Inc. and trading under Nasdaq: TVRD. This merger aims to advance Tvardi’s programs, particularly in treating idiopathic pulmonary fibrosis and hepatocellular carcinoma, with the combined entity expected to be funded into the second half of 2026.
Spark’s Take on CARA Stock
According to Spark, TipRanks’ AI Analyst, CARA is a Neutral.
Cara Therapeutics’ overall score is driven by significant financial difficulties, marked by declining revenues and persistent losses. While technical indicators show some positive momentum, the company’s poor valuation and financial instability weigh heavily on its prospects. The strategic merger with Tvardi Therapeutics, however, offers a glimmer of hope for future growth, potentially improving its market positioning and addressing unmet medical needs.
To see Spark’s full report on CARA stock, click here.
More about Cara Therapeutics
Cara Therapeutics, Inc. is a Delaware-based biopharmaceutical company that focuses on developing novel therapies. It has entered into a merger agreement with Tvardi Therapeutics, a clinical-stage biopharmaceutical company specializing in oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases.
YTD Price Performance: -9.24%
Average Trading Volume: 23,782
Technical Sentiment Signal: Buy
Current Market Cap: $22.41M
For a thorough assessment of CARA stock, go to TipRanks’ Stock Analysis page.